2024
Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study
McEntegart M, Gonzalo N, Fendelander L, West N, Lansky A. Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 102289. DOI: 10.1016/j.jscai.2024.102289.Peer-Reviewed Original ResearchCoronary artery diseaseCalcified coronary artery diseasePercutaneous coronary interventionTarget lesion failureCoronary intravascular lithotripsyArtery diseaseFemale patientsIntravascular lithotripsySubcohort analysis of patientsPrevalence of coronary artery calcificationEnd pointsOptical coherence tomography imagesComposite of cardiac deathClinical events committeeSafety end pointAnalysis of patientsIndependent core laboratoryIncreased risk of mortalityIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionTarget lesion revascularizationCoronary artery calcificationEffectiveness end pointCAD studiesCardiology clinical trialsLong-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial)
Patel K, Lansky A, Kelbæk H, Xu B, van Royen N, Johnson T, Anderson R, Wijns W, Baumbach A, Investigators T. Long-Term Percutaneous Coronary Intervention Outcomes in Chronic Versus Acute Coronary Syndromes (TARGET All Comers Trial). The American Journal Of Cardiology 2024, 217: 94-101. PMID: 38350507, DOI: 10.1016/j.amjcard.2023.12.002.Peer-Reviewed Original ResearchChronic coronary syndromeAcute coronary syndromeTarget lesion failureSirolimus-eluting stentsEverolimus-eluting stentIschemia-driven target lesion revascularizationTarget lesion revascularizationCoronary syndromeDefinite/probable stent thrombosisStent thrombosisClinical presentationLesion revascularizationFIREHAWK stentAcute coronary syndrome presentationSpectrum of clinical presentationsAcute coronary syndrome populationXIENCE stentAcute coronary syndrome cohortLong-term PCI outcomesLong-term outcomesLong-term safetyOpen-labelPatient-oriented outcomesBaseline characteristicsAdverse events
2023
Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes
Frampton J, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Lesions: Long-Term Sex-Specific Outcomes. Journal Of The Society For Cardiovascular Angiography & Interventions 2023, 2: 101069. PMID: 39129889, PMCID: PMC11307843, DOI: 10.1016/j.jscai.2023.101069.Peer-Reviewed Original ResearchIntravascular lithotripsyLesion failureIschemia-driven target lesion revascularizationMajor adverse cardiac event ratesAdverse cardiac event ratesDrug-eluting stent placementMajor adverse cardiac eventsSmaller reference vessel diameterTarget vessel myocardial infarctionCoronary intravascular lithotripsyAdverse cardiac eventsCardiac event ratePrimary end pointTarget lesion failureTarget lesion revascularizationVessel myocardial infarctionReference vessel diameterAdverse clinical eventsHigh procedural successSex-based outcomesSex-specific outcomesLesion revascularizationAngiographic outcomesCardiac eventsCardiac death
2022
Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III
Garot P, Leon M, Saito S, Baumbach A, Kereiakes D, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Diaz V, McLaurin B, Cequier A, Hofma S, Dib N, Namiki A, Takahashi A, Kakuta T, Hirohata A, Lansky A. Geographic Variations on the Safety and Efficacy of the Supreme Biodegradable Polymer DES: Results From PIONEER III. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 2: 100515. PMID: 39132534, PMCID: PMC11308104, DOI: 10.1016/j.jscai.2022.100515.Peer-Reviewed Original ResearchDrug-eluting stentsDurable polymer everolimus-eluting stentsEverolimus-eluting stentsIII trialsLesion failureClinical outcomesMyocardial infarctionMajor adverse cardiac eventsVessel-related myocardial infarctionBiodegradable polymer drug-eluting stentsAdverse cardiac eventsOutcomes of patientsTarget lesion failureTarget lesion revascularizationLesion revascularizationCardiac eventsPatient characteristicsCardiac deathDES groupProcedural successStent thrombosisSubgroup analysisPatient outcomesNonsignificant trendEnrollment locationSafety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus
Thomas A, Kereiakes D, Baumbach A, Windecker S, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Cequier Á, Takahashi A, Cannon L, Amoroso G, Kakuta T, Saito S, Leon M, Lansky A. Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100033. PMID: 39132558, PMCID: PMC11307809, DOI: 10.1016/j.jscai.2022.100033.Peer-Reviewed Original ResearchTarget vessel myocardial infarctionVessel myocardial infarctionDiabetes mellitusDP-EESLesion failureIII trialsCardiac deathMyocardial infarctionBiodegradable Polymer Sirolimus-Eluting StentBiodegradable polymer sirolimus-eluting stentsTarget lesion failureTarget lesion revascularizationPercutaneous coronary interventionSirolimus-Eluting StentsLong-term inflammatory responseDiabetic subgroupsLesion revascularizationNondiabetic patientsSecondary endpointsBackground PatientsCoronary interventionPrespecified analysisComposite endpointPrimary safetyWorse outcomesOutcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
Patel K, Lansky A, Kereiakes D, Windecker S, Cristea E, Pietras C, Dressler O, Issever M, Curtis M, Bertolet B, Zidar J, Smits P, Díaz V, McLaurin B, Brogno D, Janssens L, Vrolix M, Gómez-Blázquez I, Sahul Z, Kabour A, Salido L, Cleman M, Saito S, Leon M, Baumbach A, Investigators I. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100004. PMID: 39130138, PMCID: PMC11308031, DOI: 10.1016/j.jscai.2021.100004.Peer-Reviewed Original ResearchDrug-eluting stentsTarget lesion failureDP-EESComplex lesionsLesion failureAdverse eventsLesion complexityMajor adverse cardiac eventsSingle-blind clinical trialEnd pointAdverse cardiac eventsChronic coronary syndromePrimary end pointSecondary end pointsTarget lesion revascularizationTarget vessel failureComplex coronary lesionsPercutaneous coronary interventionEverolimus-eluting stentsDrug eluting stentsHigh rateLesion revascularizationCoronary syndromeCardiac eventsCoronary intervention
2021
Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study
Kandzari DE, Alaswad K, Jaffer FA, Brilakis E, Croce K, Kearney K, Spaedy A, Yeh R, Thompson C, Nicholson W, Wyman RM, Riley R, Lansky A, Buller C, Karmpaliotis D. Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. Catheterization And Cardiovascular Interventions 2021, 99: 263-270. PMID: 34582080, DOI: 10.1002/ccd.29962.Peer-Reviewed Original ResearchConceptsMyocardial infarctionGuidewire recanalizationProcedural successCatheter extensionChronic total coronary occlusion revascularizationChronic total occlusion (CTO) percutaneous revascularizationFavorable procedural successGuide catheter extensionHigher lesion complexityHospital cardiac deathProspective registration studyTotal Occlusion StudyTarget lesion revascularizationPrevalence of diabetesPrior myocardial infarctionSingle-arm studyTIMI grade 2Femoral arterial accessJ-CTO scorePrevious bypass surgeryNon-CTO PCIHospital MACELesion revascularizationCTO revascularizationHemodynamic instabilityNovel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease
Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB, Investigators O. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease. Circulation 2021, 143: 2143-2154. PMID: 33820424, DOI: 10.1161/circulationaha.120.052482.Peer-Reviewed Original ResearchConceptsDurable polymer everolimus-eluting stentsDrug-eluting stentsTarget lesion revascularizationAntiproliferative drug deliveryChronic coronary syndromeVessel myocardial infarctionLesion revascularizationCoronary syndromeLesion failureMyocardial infarctionDrug-Eluting Stent ImplantationTarget vessel myocardial infarctionLong-term clinical outcomesDP-EES groupPrimary end pointTarget lesion failureSmooth muscle cell proliferationPercutaneous coronary interventionSingle-blind trialCoronary artery diseaseEverolimus-eluting stentsMuscle cell proliferationLong-term inflammatory responseDrug eluting stentsCardiovascular deathWall shear stress estimated by 3D-QCA can predict cardiovascular events in lesions with borderline negative fractional flow reserve
Tufaro V, Safi H, Torii R, Koo BK, Kitslaar P, Ramasamy A, Mathur A, Jones DA, Bajaj R, Erdoğan E, Lansky A, Zhang J, Konstantinou K, Little CD, Rakhit R, Karamasis GV, Baumbach A, Bourantas CV. Wall shear stress estimated by 3D-QCA can predict cardiovascular events in lesions with borderline negative fractional flow reserve. Atherosclerosis 2021, 322: 24-30. PMID: 33706080, DOI: 10.1016/j.atherosclerosis.2021.02.018.Peer-Reviewed Original ResearchConceptsNegative fractional flow reserveCardiovascular eventsFractional flow reservePrimary endpointFlow reserveSmaller minimum lumen areaAdverse cardiovascular eventsRetrospective cohort studyTarget lesion revascularizationOnly independent predictorMinimum lumen areaQCA variablesAngiographic characteristicsLesion revascularizationCulprit lesionHighest maximum wall shear stressCohort studyCardiac deathIndependent predictorsComplete followMultivariable analysisMyocardial infarctionTarget lesionsArea stenosisNegative FFRDifferential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy
Saito Y, Wijns W, Baumbach A, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Differential impact of abluminal groove‐filled biodegradable‐polymer sirolimus‐eluting stent versus durable‐polymer everolimus‐eluting stent on and off dual antiplatelet therapy. Catheterization And Cardiovascular Interventions 2021, 99: 357-365. PMID: 33502809, DOI: 10.1002/ccd.29468.Peer-Reviewed Original ResearchConceptsDual antiplatelet therapyTarget lesion failureDrug-eluting stentsTarget vessel myocardial infarctionBiodegradable polymer drug-eluting stentsChronic coronary syndromeAcute coronary syndromeDAPT discontinuationVessel myocardial infarctionAntiplatelet therapyCoronary syndromeMyocardial infarctionDurable polymer drug-eluting stentsIschemia-driven target lesion revascularizationIschemic coronary artery diseaseTarget lesion revascularizationIschemia-driven revascularizationPercutaneous coronary interventionCoronary artery diseaseIschemic coronary diseaseComer studyLesion revascularizationDAPT durationLesion failurePrimary endpoint
2019
2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W, Investigators T. 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC Cardiovascular Interventions 2019, 12: 1679-1687. PMID: 31129092, DOI: 10.1016/j.jcin.2019.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary ThrombosisDrug-Eluting StentsDual Anti-Platelet TherapyEuropeEverolimusFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureXIENCE stentXience groupLesion failurePrimary endpointClinical outcomesIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionLong-term outcomesDurable polymer everolimusBiodegradable Polymer SirolimusAbluminal grooveFIREHAWK stentLesion revascularizationCardiac deathComparable safetyStent thrombosisMyocardial infarctionClinical trialsEfficacy profileNoninferiority trialLandmark analysisBalloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study
Laird JR, Zeller T, Holden A, Scheinert D, Moore E, Mendes R, Schmiedel R, Settlage R, Lansky A, Jaff MR, Investigators B, Elmasri F, Robinson W, Beasley R, Mego D, Marica S, Bersin R, Kujath S, Razavi M, Teßarek J, Schulte K. Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study. Journal Of Vascular And Interventional Radiology 2019, 30: 836-844.e1. PMID: 30956077, DOI: 10.1016/j.jvir.2018.12.031.Peer-Reviewed Original ResearchConceptsMajor adverse eventsWalking Impairment QuestionnaireQuality of lifeLesion revascularizationPrimary patencyMyocardial infarctionIliac artery occlusive diseaseComposite endpoint rateProcedure-related deathsTarget lesion revascularizationArtery occlusive diseaseSingle-arm studyMajor amputationRutherford categoryOcclusive lesionsPrimary endpointSecondary endpointsAdverse eventsClinical improvementImpairment QuestionnaireOcclusive diseaseClinical outcomesMulticenter studyEndpoint rateIliac artery
2018
A prospective, multi‐center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry
Mustapha JA, Lansky A, Shishehbor M, McClure J, Johnson S, Davis T, Makam P, Crowder W, Konstantino E, Attaran RR, Investigators T. A prospective, multi‐center study of the chocolate balloon in femoropopliteal peripheral artery disease: The Chocolate BAR registry. Catheterization And Cardiovascular Interventions 2018, 91: 1144-1148. PMID: 29513389, DOI: 10.1002/ccd.27565.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonEquipment DesignFemaleFemoral ArteryHumansMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProduct Surveillance, PostmarketingProspective StudiesRegistriesRisk FactorsStentsTime FactorsTreatment OutcomeUnited StatesVascular Access DevicesVascular PatencyConceptsTarget lesion revascularizationPrimary endpointFemoropopliteal peripheral artery diseaseSymptomatic peripheral arterial diseaseExcellent procedural outcomesLower dissection ratePeripheral arterial diseasePeripheral artery diseaseAcute procedural successLong-term outcomesPost-market registryMulti-center studyAngioplasty balloon catheterPercutaneous transluminal angioplasty balloon catheterRutherford classCause mortalityLesion revascularizationMajor amputationArtery diseaseArterial diseaseProcedural successUnplanned amputationBalloon catheterProcedural outcomesProcedure success
2017
Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial
Laird JR, Zeller T, Loewe C, Chamberlin J, Begg R, Schneider PA, Nanjundappa A, Bunch F, Schultz S, Harlin S, Lansky A, Jaff MR. Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. Journal Of Endovascular Therapy 2017, 25: 68-78. PMID: 29285955, DOI: 10.1177/1526602817749242.Peer-Reviewed Original ResearchConceptsTarget lesion revascularizationMajor adverse eventsProximal popliteal arteryPrimary patencyPopliteal arteryStent fractureAnkle/brachial indexPrimary safety endpointPrimary efficacy endpointTreatment of lesionsQuality of lifeSame time pointsLesion revascularizationRutherford categoryEfficacy endpointSafety endpointSecondary endpointsAdverse eventsBrachial indexSuperficial femoralProcedure successFracture ratesClinical successControl groupArteryImpact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions
Kitahara H, Okada K, Kimura T, Yock PG, Lansky AJ, Popma JJ, Yeung AC, Fitzgerald PJ, Honda Y. Impact of Stent Size Selection on Acute and Long-Term Outcomes After Drug-Eluting Stent Implantation in De Novo Coronary Lesions. Circulation Cardiovascular Interventions 2017, 10: e004795. PMID: 28951394, DOI: 10.1161/circinterventions.116.004795.Peer-Reviewed Original ResearchConceptsDrug-eluting stent implantationReference vessel diameterLong-term outcomesDe novo coronary lesionsNovo coronary lesionsStent implantationDrug-eluting stentsIncomplete stent appositionClinical outcomesCoronary lesionsStent thrombosisStent oversizingStent appositionAngiographic reference vessel diameterSmaller reference vessel diameterGreater stent expansionLesion revascularization rateTarget lesion revascularizationGreater adverse eventsSerial coronary angiographyArterial wall injuryStent size selectionLesion revascularizationRevascularization ratesAdverse events
2015
Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials
Gao Z, Zhang R, Xu B, Yang Y, Ma C, Li H, Chen S, Han Y, Yuan Z, Lansky AJ, Guan C, Leon MB, Gao R, Investigators F. Safety and efficacy of a novel abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent for the treatment of de novo coronary lesions: Two‐year results from a prospective patient‐level pooled analysis of TARGET trials. Catheterization And Cardiovascular Interventions 2015, 85: 734-743. PMID: 25678281, DOI: 10.1002/ccd.25861.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsChinaCoronary Artery DiseaseDrug-Eluting StentsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRandomized Controlled Trials as TopicRegistriesRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureFIREHAWK stentStent thrombosisCoronary lesionsMyocardial infarctionNovel abluminal groove-filled biodegradable polymer sirolimus-eluting stentDe novo native coronary lesionsBiodegradable polymer sirolimus-eluting stentsDe novo coronary lesionsPatient-level pooled analysisTarget vessel myocardial infarctionNew drug-eluting stentsNative coronary lesionsNovo coronary lesionsProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionSirolimus-eluting stentsPatient-level analysisPatient-level dataLong-term safetyDrug-eluting stentsTwo-year resultsObjective performance criteriaLesion revascularization
2014
Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes Pooled Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trials
Généreux P, Madhavan MV, Mintz GS, Maehara A, Palmerini T, LaSalle L, Xu K, McAndrew T, Kirtane A, Lansky AJ, Brener SJ, Mehran R, Stone GW. Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes Pooled Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trials. Journal Of The American College Of Cardiology 2014, 63: 1845-1854. PMID: 24561145, DOI: 10.1016/j.jacc.2014.01.034.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionSevere target lesion calcificationAcute coronary syndromePercutaneous coronary interventionTarget lesion calcificationTarget lesion revascularizationElevation acute coronary syndromeDefinite stent thrombosisLesion calcificationStent thrombosisHORIZONS-AMICoronary syndromeCoronary interventionCoronary calcificationST-segment elevation acute coronary syndromeSegment elevation acute coronary syndromesIndependent angiographic core laboratoryStable coronary artery diseaseSevere lesion calcificationOne-year outcomesElevation myocardial infarctionCoronary artery diseaseAngiographic core laboratoryACUITY trialIschemic outcomes
2013
The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
Ng VG, Lansky AJ, Meller S, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie B, Shah R, Mehran R, Stone GW. The prognostic importance of left ventricular function in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. European Heart Journal Acute Cardiovascular Care 2013, 3: 67-77. PMID: 24562805, PMCID: PMC3932775, DOI: 10.1177/2048872613507149.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntithrombinsCoronary AngiographyDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesGated Blood-Pool ImagingHirudinsHumansMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPrognosisProspective StudiesRecombinant ProteinsTreatment OutcomeVentricular Function, LeftConceptsST-segment elevation myocardial infarctionLeft ventricular ejection fractionPaclitaxel-eluting stentsHORIZONS-AMI trialElevation myocardial infarctionLV dysfunctionLV functionMyocardial infarctionIschaemia-driven target lesion revascularizationMajor adverse cardiovascular eventsNet adverse clinical eventsPrimary percutaneous coronary interventionBaseline LV dysfunctionIndex revascularization procedureAdverse cardiovascular eventsOutcomes of patientsTarget lesion revascularizationHigh-risk patientsSubstantial clinical benefitAdverse clinical eventsNormal LV functionPercutaneous coronary interventionVentricular ejection fractionLeft ventricular functionBare metal stentsMeta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)
Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease Final 3-Year Results of the SPIRIT Clinical Trials Program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovascular Interventions 2013, 6: 914-922. PMID: 24050859, DOI: 10.1016/j.jcin.2013.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary RestenosisCoronary ThrombosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisMyocardial InfarctionPaclitaxelPercutaneous Coronary InterventionProportional Hazards ModelsProsthesis DesignRandomized Controlled Trials as TopicRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsIschemia-driven target lesion revascularizationMajor adverse cardiac eventsAdverse cardiac eventsTarget lesion revascularizationLesion failureMyocardial infarctionLesion revascularizationCause mortalityCardiac eventsStent thrombosisStent typeEvent ratesTarget lesion failureClinical trial programException of diabetesIndividual patient dataIndividual clinical outcomesCardiac deathComposite endpointClinical outcomesSPIRIT IIClinical trialsCoronary implantationTrial programDrug eluting balloons for de novocoronary lesions – a systematic review and meta-analysis
Fröhlich GM, Lansky AJ, Ko DT, Archangelidi O, De Palma R, Timmis A, Meier P. Drug eluting balloons for de novocoronary lesions – a systematic review and meta-analysis. BMC Medicine 2013, 11: 123. PMID: 23657123, PMCID: PMC3648374, DOI: 10.1186/1741-7015-11-123.Peer-Reviewed Original ResearchConceptsMajor adverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationBare metal stentsLate lumen lossDrug-eluting balloonsDe novo coronary lesionsCurrent standard therapyDrug-Eluting BalloonRelative riskCoronary lesionsStent thrombosisMyocardial infarctionStandard therapyStent restenosisSystematic reviewLower late lumen lossAdverse cardiac eventsPooled relative riskRandom-effects modelLesion revascularizationSegment restenosisCardiac eventsComparator treatmentResultsEight studies